Your SlideShare is downloading. ×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Biopharma musculoskeletal disorders_4-30-2013

456
views

Published on

Better cell cultures lower your research costs!-A common Neuromics' theme is harnessing the power of cells. The raw cost of the cells are often the biggest consideration. We encourage our customers to …

Better cell cultures lower your research costs!-A common Neuromics' theme is harnessing the power of cells. The raw cost of the cells are often the biggest consideration. We encourage our customers to focus on true costs. These include the # number of cells (how many times can they be passaged?), culture viability (how long do the cells live) and bioactivity (how closely do cultures mimic in vivo behavior?). I would like to present a publication and presentation confirms our competitiveadvantage when analyzing true costs.

Published in: Technology, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
456
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Harnessing the Power ofCellsTMNew Assays forMusculoskeletal Disorders DrugDiscoveryExecutive Overview1
  • 2. Solutions for Musculoskeletal Disease ResearchPotent Umbilical Cord Blood Derived Human Mesenchymal Stem Cells Alternative to induced pluripotent and embryonic stem cells Phenotypically and morphologically stable through 50 population doublings i.e. CD44, CD45,CD71 and CD105 expressing. Capacity to produce cell numbers required for high throughput& content screeningDifferentiated Cells: Osteoblasts, Chondrocytes and FibroblastsPotent Media Low serum and clinical grade, serumfree expansion media Osteogenesis, chondrogenesis &adipogenesis media Stem cell basal mediaMSCGroTM Media vs Lonza1 4/30/2013 2
  • 3. Potent Cells and Media-Better Results=Lower Costs2 4/30/2013 3Our Media Keeps your Cells Going and Going “We tested theeffects of MSCTMGro defined medium using several differentlots of human adult primary stem cells and found thatMSCGro supports a more robust proliferation rate thannormal undefined media. This provided shorter doublingtimes and increased cellular yield, and maintained the cells inan undifferentiated state. We also found that MSCGromedium is stable under normal laboratory conditions for anextended time period compared to other defined media.” BenBuehrer, VP and CSO, Zen-BioImages: (A) Human cord-blood MSCs were expanded inlow-serum MSC-GroTM to confluence as shown here. (B)were differentiated in osteogenic MSC-GroTM. Early stageosteoblasts are shown here; the arrow shows earlyformation of mineralized matrix. (C)&(D) Matureosteoblasts stained positive for Alizarin red. Phase contrastimage at 200 x, scale bar is 50 mmeters.
  • 4. Potent Cells and Media-Summary3 4/30/2013 4Cells are differentiated from human MSCs-Competitive to IPSCs since there is noreprogramming nor epigenetic issues intrinsic toIPSCsCost-effective due to manufacturing scalabilityDirect purchase without licensing requirementHighly experienced team with extensive technical andbiopharma partnership experience.Cell therapy application as well as discovery.
  • 5. Capabilities meet HCS/HTS Requirements Cost-effective materials to meet target per well costs Human cells reduce false positives vs. animal tissues Cells express proteins of interest. Verification assays providedbased on specific requirements. Readily scalable: Identical phenotype/genotype from pilot toscreening mode. Co-culture capability for custom assays. E.g., chondrocyte/osteoblasts4 4/30/2013 5
  • 6. Evaluation Process Confidential discussion of Specific Disorder, Therapeutic Target(s) and cellbased assay requirements. Design pilot assay with deliverables and milestones Review milestone data vs requirements Revise assay as needed Determine final assay configuration. Determine scale up requirements Cost targets Material and deliverables Evaluate progress vs plans and adjust accordingly Position capabilities for future projects5 4/30/2013 6
  • 7. ContactsTechnical and Consulting:Dr. Jim MusickPresidentVitro Biopharmajim@vitrobiopharma.com(303) 999-21304621 Technology DriveGolden, CO 80403Sales/Proposal ProcessPete ShusterCEONeuromicspshuster@neuromics.com612-801-10075325 West 74ths StreetEdina, MN 55439Draft 1 04-2013-3 7